Navigating 7 Analyst Ratings For Stryker
Portfolio Pulse from Benzinga Insights
Stryker (NYSE:SYK) has received mixed analyst ratings over the past three months, with 7 analysts offering views ranging from bullish to indifferent. The average 12-month price target for SYK has increased by 10.1% to $324.57, with a high estimate of $345.00 and a low of $297.00. Analysts from RBC Capital, Truist Securities, Morgan Stanley, Roth MKM, and UBS have adjusted their ratings and price targets, reflecting a positive outlook on the company's performance. Stryker is a major player in medical equipment and has shown strong financial indicators such as a 9.6% revenue growth rate, a net margin of 14.1%, and an ROA of 1.83%, but a lower-than-average ROE of 3.92% and a conservative debt-to-equity ratio of 0.71.

January 12, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stryker has received a range of analyst ratings, with a positive shift in the average 12-month price target to $324.57. The company's strong financial performance is likely to support a positive short-term impact on the stock price.
The increase in the average price target by analysts suggests a bullish sentiment towards Stryker's stock. The company's solid financial metrics, such as revenue growth and net margin, reinforce this positive outlook. Given the recent updates from analysts and the company's financial strength, there is a high likelihood of a positive short-term impact on SYK's stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100